Telix Pharmaceuticals Limited vs ADMA Biologics, Inc.: Examining Key Revenue Metrics

Biotech Revenue Surge: Telix vs. ADMA from 2014 to 2023

__timestampADMA Biologics, Inc.Telix Pharmaceuticals Limited
Wednesday, January 1, 2014591554528336824
Thursday, January 1, 2015717763332319194
Friday, January 1, 20161066103729404631
Sunday, January 1, 20172276056031769230
Monday, January 1, 20181698529020439380
Tuesday, January 1, 20192934908324186536
Wednesday, January 1, 2020422197834680000
Friday, January 1, 2021809426254898000
Saturday, January 1, 2022154079692155984000
Sunday, January 1, 2023258214999496659000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, Telix Pharmaceuticals Limited and ADMA Biologics, Inc. have showcased remarkable revenue trajectories over the past decade. From 2014 to 2023, Telix Pharmaceuticals experienced a staggering growth, culminating in a 1,650% increase in revenue by 2023. Meanwhile, ADMA Biologics also demonstrated impressive growth, with a 4,260% rise in revenue during the same period.

Key Insights

  • Telix Pharmaceuticals: Starting with a modest revenue in 2014, Telix's revenue surged to nearly $500 million by 2023, highlighting its strategic advancements in the biotech sector.
  • ADMA Biologics: With a consistent upward trend, ADMA's revenue reached approximately $258 million in 2023, reflecting its robust market presence.

This comparison underscores the potential and resilience of biotech companies in navigating market challenges and capitalizing on growth opportunities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025